Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology

Mun, Yongseok; You, Seng Chan; Lee, Da Yun; Kim, Seok; Chung, Yoo‐Sam; Lee, Kihwang; Song, Jongtae; Park, Young Gun; Roh, Yong Kyun; Woo, Se Joon; Park, Kyu Hyung; Park, Rae Woong; Yoo, Sooyoung; Chang, Dong Jin; Park, Sang Jun

doi:10.4178/epih.e2021097

Cited by 9 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The OMOP CDM adopts standardized structures, contents, and semantics of observational data. This feature permits researchers to share their analysis codes across disparate observational healthcare databases when their healthcare data are properly extracted, transformed, and loaded in accordance with the OMOP CDM 20 . A number of large-scale collaborative studies across different data sources have been conducted, and real-world evidence has been generated using OMOP CDM 21 , 22 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology

Mun

Park

Lee

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Despite many studies, optimal treatment sequences or intervals are still questionable in retinal vein occlusion (RVO) macular edema. The aim of this study was to examine the real-world treatment patterns of RVO macular edema. A retrospective analysis of the Observational Medical Outcomes Partnership Common Data Model, a distributed research network, of four large tertiary referral centers (n = 9,202,032) identified 3286 eligible. We visualized treatment pathways (prescription volume and treatment sequence) with sunburst and Sankey diagrams. We calculated the average number of intravitreal injections per patient in the first and second years to evaluate the treatment intensities. Bevacizumab was the most popular first-line drug (80.9%), followed by triamcinolone (15.1%) and dexamethasone (2.28%). Triamcinolone was the most popular drug (8.88%), followed by dexamethasone (6.08%) in patients who began treatment with anti-vascular endothelial growth factor (VEGF) agents. The average number of all intravitreal injections per person decreased in the second year compared with the first year. The average number of injections per person in the first year increased throughout the study. Bevacizumab was the most popular first-line drug and steroids were considered the most common as second-line drugs in patients first treated with anti-VEGF agents. Intensive treatment patterns may cause an increase in intravitreal injections.

show abstract

Section: Introductionmentioning

confidence: 99%

“…A number of large-scale collaborative studies across different data sources have been conducted, and real-world evidence has been generated using OMOP CDM 21 , 22 . Recently, a study has been conducted using data from the OMOP CDM to analyze the real-world incidence of endophthalmitis following anti-VEGF therapy 20 .…”

Section: Introductionmentioning

confidence: 99%

Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology

Mun

Park

Lee

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Other studies have used large administrative claims databases [33,34] or electronic medical records databases. [35,36] Our study is the first that used the OMOP CDM to harmonize nonstandardized national disease registries.…”

Section: Discussionmentioning

confidence: 99%

“…However, over the last couple of years, an increasing number of publications have appeared using the OHDSI/OMOP CDM in prospective network studies with observational patient data, in particular related to the COVID-19 pandemic [ 28 – 32 ]. Other studies have used large administrative claims databases [ 33 , 34 ] or electronic medical records databases [ 35 , 36 ]. A recent study described the technicalities of harmonising standardised disease registries [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Blueprint for harmonising unstandardised disease registries to allow federated data analysis: prepare for the future

Kroes

Bansal²,

Berret

et al. 2022

ERJ Open Res

View full text Add to dashboard Cite

Real-world evidence from multinational disease registries is becoming increasingly important not only for confirming the results of randomized controlled trials, but also for identifying phenotypes, monitoring disease progression, predicting response to new drugs, and early detection of rare side effects. With new open access technologies, it has become feasible to harmonize patient data from different disease registries and use it for data analysis without compromising privacy rules. In this article, we provide a blueprint for how a clinical research collaboration can successfully use real-world data from existing disease registries to perform federated analyses. We describe how the European Severe Asthma Clinical Research Collaboration SHARP fulfilled the harmonization process from non-standardized clinical registry data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) and built a strong network of collaborators from multiple disciplines and countries. The blueprint covers organizational, financial, conceptual, technical, analytical and research aspects and discusses both the challenges and the lessons learned. All in all, setting up a federated data network is a complex process that requires thorough preparation, but above all, it is a worthwhile investment for all clinical research collaborations, especially in view of the emerging applications of artificial intelligence and federated learning.

show abstract

“…There are already examples where the OMOP CDM has been used for clinical benefit in ophthalmology. Mun et al used OMOP CDM databases to estimate the incidence of endophthalmitis after intravitreal anti-VEGF injections [10]. From a database of 8 million patients across 3 hospitals, they identified 23,490 patients who had received anti-VEGF injections with data available to analyze.…”

Section: Data Standardizationmentioning

confidence: 99%

Towards effective data sharing in ophthalmology: data standardization and data privacy

Halfpenny

Baxter

2022

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of reviewThe purpose of this review is to provide an overview of updates in data standardization and data privacy in ophthalmology. These topics represent two key aspects of medical information sharing and are important knowledge areas given trends in data-driven healthcare.Recent findingsStandardization and privacy can be seen as complementary aspects that pertain to data sharing. Standardization promotes the ease and efficacy through which data is shared. Privacy considerations ensure that data sharing is appropriate and sufficiently controlled. There is active development in both areas, including government regulations and common data models to advance standardization, and application of technologies such as blockchain and synthetic data to help tackle privacy issues. These advancements have seen use in ophthalmology, but there are areas where further work is required.SummaryInformation sharing is fundamental to both research and care delivery, and standardization/privacy are key constituent considerations. Therefore, widespread engagement with, and development of, data standardization and privacy ecosystems stand to offer great benefit to ophthalmology.

show abstract

Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology

Cited by 9 publications

References 26 publications

Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology

Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology

Blueprint for harmonising unstandardised disease registries to allow federated data analysis: prepare for the future

Towards effective data sharing in ophthalmology: data standardization and data privacy

Contact Info

Product

Resources

About